FLT3 Inhibitors in the Treatment of AML.
Gilliland
Dwight Gary
DG
Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
D000208:Acute Disease; D000911:Antibodies, Monoclonal; D002986:Clinical Trials as Topic; D004252:DNA Mutational Analysis; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics*; D051941:fms-Like Tyrosine Kinase 3
D000911:Antibodies, Monoclonal; D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3